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The Mortality-to-Incidence Ratio Is Not a Valid
Proxy for Cancer Survival
Libby Ellis, PhD1; Aure´lien Belot, PhD1; Bernard Rachet, PhD, MD1; and Michel P. Coleman, BM, BCh1
abstract
PURPOSE The ratio of cancer mortality and cancer incidence rates in a population has conventionally been used
as an indicator of the completeness of cancer registration. More recently, the complement of the mortality-to-
incidence ratio (1-M/I) has increasingly been presented as a surrogate for cancer survival. We discuss why this is
mistaken in principle and misleading in practice.
METHODS We provide an empirical assessment of the extent to which trends in the 1-M/I ratio reﬂect trends in
cancer survival. We used national cancer incidence, mortality and survival data in England to compare trends in
both the 1-M/I ratio and net survival at 1, 5, and 10 years for 19 cancers in men and 20 cancers in women over
the 29-year period from 1981 to 2009.
RESULTS The absolute difference between the 1-M/I ratio and 5-year net survival for 2009 was less than 5% for
only 12 of the 39 cancer/sex combinations examined. For an additional 12, the 1-M/I ratio differed from 5-year
net survival by at least 15%. The comparison is also unstable over time; thus, even when differences were small
for 2009, the difference between 5-year net survival and the 1-M/I ratio had changed dramatically for most
cancers between 1981 and 2009.
CONCLUSION The 1-M/I ratio lacks any theoretical basis as a proxy for cancer survival. It is not a valid proxy for
cancer survival in practice, either, whether at 5 years or at any other time interval since diagnosis. It has none of
the useful properties of a population-based survival estimate. It should not be used as a surrogate for cancer
survival.
J Global Oncol. © 2019 by American Society of Clinical Oncology
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INTRODUCTION
Population-based cancer survival is an essential
public health indicator. Estimates of cancer survival
are derived from population-based cancer regis-
tries that record a basic data set about each per-
son resident in the territory covered by the registry
who is diagnosed with cancer, in due course in-
cluding details of the patient’s death. Together with
cancer incidence rates, also derived from cancer
registries, and cancer mortality rates derived from
death registrations, these three measures comprise
an invaluable tool kit for cancer control.1
In 1976, the ratio of the number of deaths attributed to
a given cancer in a given population and the number of
patients registered with the same cancer in the same
year in the same population was proposed as a mea-
sure of the completeness of population-based cancer
registration, in Cancer Incidence in Five Continents,
Volume III, published by the International Agency for
Research on Cancer.2 It was originally described as
“deaths in period”, but later became known as the
mortality-to-incidence ratio (M/I). The number of
deaths had to be obtained from a source independent
of the cancer registry. Where the number of cancer
deaths exceeded the number of registered patients,
cancer registration was considered likely to be in-
complete. TheM/I ratio has been widely used as a data
quality indicator in cancer registries for more than
40 years.
In 1993, in Cancer Incidence in Five Continents,
Volume VI, the M/I ratio was noted as bearing a strong
inverse association with survival.3 The authors con-
sidered that the M/I ratio for a speciﬁc cancer, “taken
in conjunction with known average survival rates,
should thus give some indication as to the com-
pleteness of registration.”3(p49) It is important to note
that the M/I ratio was not being proposed as a surro-
gate for cancer survival. On the contrary, its in-
terpretation as a measure of the completeness of
cancer registration data required local knowledge of
cancer survival in the ﬁrst place.
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The International Agency for Research on Cancer manual
on cancer registration,4 published in 1991, went further,
suggesting that if cancer registries were unable to estimate
survival directly by comprehensive follow-up of all patients
with cancer who have been registered to determine their
vital status, then the M/I ratio, which was incorrectly de-
scribed as the fatality ratio, could be used instead as an
indicator of survival (duration unspeciﬁed). Importantly,
however, the manual did acknowledge that the patients
who had been registered with cancer and the persons
certiﬁed as having died of cancer were not the same
persons, so the M/I ratio was only “an indirect description
of the general survival experience.”4(pp175-176) However,
the complement of the M/I ratio (1-M/I ratio) is now in-
creasingly often presented as if it were a valid surrogate for
cancer survival, typically for 5-year survival, although the
duration of survival is often unstated. This use of the M/I
ratio is mistaken in principle and misleading in practice.
We discuss why the 1-M/I ratio cannot be safely used as
a proxy for cancer survival, for any cancer, or at any time
since diagnosis. We also assess the extent to which levels
and trends in the 1-M/I ratio reﬂect trends in cancer survival
at 1, 5 and 10 years after diagnosis. To do this, we use the
national cancer incidence, mortality and survival data for
19 cancers in men and 20 cancers in women in England for
each of the 29 years from 1981 to 2009, to compare trends
in net survival for each cancer with trends in the 1-M/I ratio
for that cancer.
CANCER INCIDENCE AND SURVIVAL
Cancer incidence and mortality rates summarize the
numbers of new diagnoses and of deaths attributed to
cancer, respectively, that have arisen in a given year, per
100,000 population. By contrast, a cancer survival estimate
is not a rate. It is the cumulative probability of survival up to
some speciﬁed time since diagnosis, such as 5 years,
among a speciﬁed cohort of people who have all been
diagnosed with cancer. In survival studies, all persons are
exposed to the risk of death from cancer because they have
been diagnosed with it. By contrast, again, most persons in
the general population are not exposed to the risk of death
from cancer, because they have not been diagnosed with it.
This may seem obvious, but it is crucial in understanding
the distinction between a cancermortality rate and a cancer
survival estimate.1
The probability of survival of a cohort of patients with cancer
declines with time since diagnosis; therefore, a cancer
survival estimate is only useful if the time since diagnosis is
speciﬁed. By contrast, the M/I ratio for a given year is
a single number, unrelated to the time since diagnosis for
any patient. It does not reﬂect the survival experience of
patients with cancer diagnosed in any year.
The 1-M/I ratio is not a valid proxy for cancer survival for
several reasons: (1) the mortality rate does not refer to the
same patients as the incidence rate, (2) the validity of
cancer mortality rates may be questionable, (3) the cause
of death stated on death certiﬁcates is less precise than the
diagnosis recorded in cancer registry records, and (4) there
is no mathematical relationship between the M/I ratio and
survival. These points are discussed in detail in the fol-
lowing sections.
TheMortality Rate Does Not Refer to the Same Patients as
the Incidence Rate
A cancer incidence rate refers to patients who were di-
agnosed in a given year. By contrast, a cancer mortality rate
refers to people who died in that year and for whom the
death certiﬁcate mentioned a cancer that was sub-
sequently coded as the underlying cause of death. The date
of a cancer diagnosis is not recorded on the death certif-
icate. For the persons who were certiﬁed as having died of
cancer in any given year, the unknown dates of diagnosis
are backscattered through time to an unknown extent,
which depends on past trends in survival. The higher the
survival, the further back in time the dates of diagnosis will
be scattered. For example, women with breast cancer who
died in 2009 could have been diagnosed with the disease
as far back as 1994 or even earlier.1
The M/I ratio makes no allowance for this. Any rapid change
in survival will only be reﬂected in the M/I ratio when the
interval between diagnosis and death has elapsed, and this
interval will vary over time as survival improves. For cancers
with high survival, this interval is long. Conversely, for a very
lethal cancer, the mortality rate in a given year largely relates
to the same group of patients as the incidence rate; therefore,
a change in prognosis will be reﬂected in the M/I ratio more
rapidly. The intrinsic variability between cancers of different
lethality in the responsiveness of the M/I ratio to changes in
survival, and to the level of survival at any time since di-
agnosis, invalidates the 1-M/I ratio as a survival metric that
would be robust for all cancers, all countries, all calendar
periods of diagnosis, or any particular time since diagnosis.
The Validity of Cancer Mortality Rates May
Be Questionable
The validity and international comparability of cancer
mortality rates depend on three factors: (1) the com-
pleteness of death registration, (2) the accuracy of certi-
ﬁcation of the cause(s) of death, and (3) if more than
one cause of death has been certiﬁed in the causal se-
quence, the accuracy of selection and coding of the un-
derlying cause of death. The underlying cause of death is
what determines whether the death is included in the
numerator of the mortality rate for that condition (cancer or
some other cause). In most high-income countries, death
certiﬁcation is statutory, civil registration systems are efﬁ-
cient, and virtually every death is registered. Inaccuracy in
mortality rates can still arise from errors in certiﬁcation of
the cause(s) of death or inconsistencies between the
doctors who complete the death certiﬁcate. The underlying
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cause of death may also be incorrectly selected and coded,
unless automated systems are used.5-7
The 1-M/I ratio was originally suggested as a useful proxy
for survival only when population-based survival esti-
mates were unavailable.4 Today, that constraint applies
mainly to low- and middle-income countries, where death
certiﬁcation may be incomplete. According to the WHO,
two thirds of the 56 million deaths that occur every year
are not even registered.8 Only 64 of the 115 WHO
Member States reporting mortality data in 2003 had high-
quality vital registration that also included certiﬁcation of
the cause of death.9 This is largely due to insufﬁcient
resources for universal death registration and medical
certiﬁcation of the cause(s) of death.10 Only one third of
countries outside North America and Europe can pro-
duce usable mortality statistics. Half the countries in
Africa and Southeast Asia do not record the cause of
death.11
Conversely, in some low-resource countries, cancer
registration and the updating of vital status is re-
markably complete, because information is collected
through household visits by local ﬁeld staff. If cancer
incidence data are more complete than the mortality
data for the general population, the M/I ratio will reﬂect
incompleteness of mortality data, not the completeness
of the incidence data. For example, population-based
registries in India routinely report M/I ratios for all
cancers combined in the range of 15% to 30%.12 This is
not likely to represent 5-year survival for all cancers
combined in the 70% to 85% range.
The Cause of Death Stated on Death Certiﬁcates Is Less
Precise Than the Diagnosis Recorded in Cancer
Registry Records
A population-based cancer registry will usually have more
precise information on a cancer diagnosis that was made
during life than a diagnosis based solely on what is written
on the death certiﬁcate. The underlying cause of death is
therefore frequently coded to a less speciﬁc disease cat-
egory than in the cancer registry.2 A cancer mortality rate,
derived from death certiﬁcates, may then refer to a broader
category of disease than the cancer incidence rate with
which it would be compared in the M/I ratio. Mis-
classiﬁcation of the cause of death can complicate esti-
mation of cause-speciﬁc survival, even for common
cancers.13 For this reason, some cancer registries recode
the underlying cause of death provided by the national
statistics ofﬁce, using diagnostic information from the
medical record for each patient.14
One US study found that even for people known to have
been diagnosed with cancer, the underlying cause of death
on the death certiﬁcate only matched the cause of death
recorded by the cancer registry for approximately 80% of
patients (all cancers combined). The concordance varied
dramatically between cancers, from 10% to 95%.15 Agreement
was better for the most common cancers, but considerable
misclassiﬁcation was seen for less common cancers.
There Is No Mathematical Relationship Between the M/I
Ratio and Survival
There is a clearly deﬁned mathematical relationship be-
tween population-based measures of cancer incidence,
survival, and mortality.1 By contrast, to the best of our
knowledge, no mathematical relationship exists between
the M/I ratio and survival, regardless of the duration of time
since diagnosis at which survival is to be estimated. For
some cancers, the 1-M/I ratio may sometimes be numer-
ically similar to 5-year net survival, but this similarity does
not hold for other time intervals of survival since diagnosis,
or for all cancers, or even for the same cancer over calendar
time. In the absence of a deﬁnedmathematical relationship
between the M/I ratio and survival, the 1-M/I ratio is not
defensible as a surrogate for cancer survival at any time
since diagnosis.
We now examine the relationship between the 1-M/I ratio
and survival empirically. We used data on cancer in-
cidence, mortality, and survival in England, where the
registration of cancers and deaths is longstanding, of high
quality, and considered complete.
METHODS
For 19 cancers inmen and 20 cancers in women (39 cancer-
sex combinations), we compared trends in the incidence
rate, mortality rate, net survival probability at 1, 5, and
10 years after diagnosis, and 1-M/I ratio for patients di-
agnosed in England in each of the 29 years from 1981 to
2009. Individual tumor registrations for newly diagnosed
patients were obtained from the National Cancer Registry.
Individual death records were obtained from the national
mortality database at the Ofﬁce for National Statistics. Annual
incidence and mortality rates were calculated for each
cancer, sex, and 5-year age group. The M/I ratio was cal-
culated from incidence and mortality rates for all ages
combined, age standardized to the 2013 European Standard
Population.16
The vital status of all patients registered with a cancer was
ascertained up to December 31, 2013. Net survival up to
10 years after diagnosis was estimated for each of the
39 cancer-sex combinations. We used a ﬂexible excess
hazard regression model in which the year of diagnosis and
age were modeled as quantitative variables.17 Net survival
can be interpreted as survival from the cancer of interest, after
correction for the hazard of death from competing causes
(background mortality).18,19 Background mortality is taken
from general population life tables of all-cause death rates,
deﬁned by single year of age, sex, and calendar year. This is
crucial in the comparison of survival estimates between
countries, or over time in the same country, because back-
ground mortality varies widely by age and sex, as well as
between countries and over time. Where fewer than 10 years
of follow-up were available, the model was used to predict
Mortality-to-Incidence Ratio Is Not a Proxy for Cancer Survival
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net survival up to 10 years after diagnosis. Cancer survival
estimates for all ages combined were age standardized with
the International Cancer Survival Standard weights.20
The cancer incidence rates and cancer survival probabil-
ities for each calendar year from 1981 to 2009 refer to the
patients who were diagnosed in that year. The cancer
mortality rates are presented for people certiﬁed as having
died from cancer in that year. Trends in age-standardized
net survival and in the 1-M/I ratio are presented alongside
trends in the age-standardized incidence and mortality
rates for selected cancers.
RESULTS
The absolute difference between the 1-M/I ratio and 5-year
net survival for 2009 was at least 5% for 27 of the
39 cancer-sex combinations examined. For 12 of these
39 cancer-sex combinations, the difference was 15% or
more: stomach, colon, liver, bladder, and brain in both
sexes; cervical cancer; and rectum in men (Table 1). For
many cancers, the difference between the two statistics
varied between men and women.
Five-Year Net Survival and the 1-M/I Ratio Differed by
Less Than 5%
The difference between the 1-M/I ratio and 5-year net
survival for patients diagnosed in 2009 was less than 5% for
12 cancer-sex combinations: esophagus, pancreas, and
Hodgkin disease in both sexes; melanoma, breast, ovary
and non-Hodgkin lymphoma in women; and testis and
thyroid in men. Most of these cancers have a good
TABLE 1. Absolute Difference (%) Between the 1-M/I Ratio (%) in 2009 and Age-Standardized 5-Year Net Survival (%) for Patients Diagnosed in
2009, by Cancer and Sex
Absolute Difference
Men Women
1-M/I Ratio 5-year NS Difference 1-M/I Ratio 5-year NS Difference
Less than 5% difference*
Esophagus 8.4 13.3 −4.9 13.4 15.6 −2.2
Pancreas 7.4 4.4 3.1 6.7 4.7 2.0
Melanoma 84.8 77.7 7.0 89.5 85.6 3.9
Breast (women) . . . 79.2 78.1 1.1
Ovary . . . 43.1 43.9 −0.8
Testis 96.6 95.3 1.3 . . .
Thyroid 77.6 74.4 3.2 88.9 81.8 7.1
Hodgkin disease 79.8 79.7 0.1 84.4 82.9 1.5
Non-Hodgkin lymphoma 61.3 55.4 5.9 65.2 61.0 4.2
5%-14.9% difference
Larynx (men) 68.4 58.2 10.2 . . .
Lung 15.5 9.5 6.1 21.0 12.3 8.7
Uterus . . . 78.8 71.4 7.4
Prostate 73.2 66.8 6.4 . . .
Kidney 62.9 48.7 14.3 61.9 51.7 10.2
Multiple myeloma 49.7 37.7 12.1 46.0 37.9 8.2
Leukemia 47.5 40.1 7.4 48.0 40.7 7.3
Difference of 15% or more †
Stomach 37.9 17.2 20.8 37.7 18.6 19.1
Colon 64.9 45.6 19.3 66.1 47.6 18.5
Rectum 63.7 48.5 15.2 63.4 51.4 12.0
Liver 38.7 11.2 27.5 41.7 10.2 31.5
Cervix . . . 97.4 64.9 32.6
Bladder 75.7 48.4 27.3 70.3 43.1 27.3
Brain 35.3 18.9 16.5 39.2 21.3 17.9
NOTE. Figures are rounded to one decimal place, but absolute differences are calculated on the exact values of the 1-M/I ratio and 5-year NS.
Abbreviations: 1-M/I ratio, complement of the mortality-to-incidence ratio; NS, net survival.
*Cancers for which the 1-M/I ratio differed by less than 5% from 5-year NS in men or women.
†Cancers for which the 1-M/I ratio differed by 15% or more from 5-year NS in men or women.
Ellis et al
4 © 2019 by American Society of Clinical Oncology
Downloaded from ascopubs.org by 140.77.64.58 on May 12, 2019 from 140.077.064.058
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
prognosis. Testicular cancer has the highest survival of all
common cancers in men (5-year net survival in 2009,
95%), and the 1-M/I ratio tracks the trend in 5-year net
survival closely (Fig 1A). Among women, melanoma of the
skin has the highest survival of all common cancers (5-year
net survival in 2009, 86%). From the early 1980s to the
mid-1990s, the 1-M/I ratio for melanoma in women was
similar to 5-year net survival, but the trends in the 1-M/I
ratio and 5-year net survival start to diverge around 1995,
after a distinct increase in incidence (Fig 1B).
Five-year net survival among women diagnosed with breast
cancer was also high (78% in 2009), and from the late
1990s onward, the 1-M/I ratio was almost identical to 5-year
net survival (Fig 1C). Before then, however, trends in the
1-M/I ratio and 5-year net survival were widely divergent.
For example, the 1-M/I ratio for breast cancer in 1984 was
almost 20% lower than the 5-year net survival estimate for
women diagnosed with breast cancer in that year.
Five-year net survival amongmen diagnosed with esophageal
cancer was just 13% in 2009. Despite some ﬂuctuation, the
trend in the 1-M/I ratio largely tracked the trend in 5-year net
survival (Fig 1D). Among the cancers we examined,
esophageal cancer was the only one for which the 1-M/I ratio
was consistently lower than 5-year net survival.
Five-Year Net Survival and the1-M/I Ratio Differed by
15% or More
For stomach cancer, trends in incidence, mortality, and
survival changed dramatically from 1981 to 2009. The
1-M/I ratio was consistently much higher than 5-year net
survival for both men (by 21% in 2009; Fig 2A) and
women (by 19% in 2009; Data Supplement).
The incidence of cervical cancer also changed consider-
ably over the 29-year period from 1981 to 2009. Although
the trends in the 1-M/I ratio and 5-year net survival followed
a broadly similar pattern, the difference in level between the
1-M/I ratio for 2009 and the 5-year net survival estimate for
women diagnosed in 2009 was as much as 32% (Fig 2B).
For cancers of the colon and rectum,mortality declined and
survival improved from 1981 to 2009. For both cancers, the
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FIG 1. Trends in age-standardized incidence, mortality, complement to mortality-to-incidence ratio (1-M/I ratio), and net survival (NS) in England, 1981 to
2009. Four cancers for which the 1-M/I ratio for 2009 differed by less than 5% from 5-year NS for patients diagnosed in 2009: (A) testicular; (B) melanoma of
the skin (women), (C) breast (women), and (D) esophagus (men). Solid blue lines, 1-, 5-, and 10-year NS; dashed brown line, 1-M/I; dashed teal line,
incidence rate; solid brown line, mortality rate.
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trend in the 1-M/I ratio roughly tracked 5-year net survival
until the early 1990s, but the trends then became in-
creasingly divergent. By 2009, the 1-M/I ratio was 19%
higher than 5-year net survival for colon cancer in both men
and women (Fig 2C; women), and 12% to 15% higher than
5-year net survival for rectal cancer (Fig 2D; men).
For liver cancer, the trends in incidence, mortality, 1-M/I
ratio, and 5-year net survival are widely discordant.
Changes in the diagnosis and recording of brain tumors,21
and changes in the deﬁnition of what is recorded as an
invasive bladder cancer also make it difﬁcult to interpret
trends in incidence and survival for these cancers in En-
gland.22 Trends in the 1-M/I ratio are vastly different from
the trends in 5-year net survival for cancers of the liver,
brain, and bladder (Data Supplement).
DISCUSSION
For most cancers, the difference between 5-year net sur-
vival and the 1-M/I ratio in England changed dramatically
between 1981 and 2009. Our analyses of trends in cancer
incidence, mortality and survival in England show that, for
more than half of 19 common cancers in men and 20
common cancers in women, the 1-M/I ratio is not even
closely similar to the estimates of 5-year net survival. The
starkest examples are for stomach cancer, for which in-
cidence and mortality rates have declined steadily, and
cervical cancer, for which incidence was increasing but has
ﬂuctuated widely. The results also show that the difference
between the 1-M/I ratio and 5-year net survival for any given
cancer can change dramatically over time.
For some cancers, changes or inaccuracy in the diagnosis,
recording, and coding of tumors in the cancer registry, and
on death certiﬁcates, make it difﬁcult to interpret trends in
incidence, mortality, and survival. Our analyses raise con-
cern about the quality of mortality data for liver cancer. This
observation is not new; in one US study, only 53% of deaths
among patients with microscopically conﬁrmed primary liver
cancer were recorded with primary liver cancer as the un-
derlying cause of death on the death certiﬁcate.23
The 1-M/I ratio was initially suggested in the 1970s as an
indicator of the completeness of population-based cancer
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FIG 2. Trends in age-standardized incidence, mortality, complement to mortality-to-incidence ratio (1-M/I ratio), and net survival (NS) in England, 1981 to
2009. Four cancers for which the 1-M/I ratio for 2009 differed by 15% or more from 5-year NS for patients diagnosed in 2009: (A) stomach (men), (B) cervix,
(C), colon (women), and (D) rectum (men). Solid blue lines, 1-, 5-, and 10-year NS; dashed brown line, 1-M/I; dashed teal line, incidence rate; solid brown
line, mortality rate.
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registries. In the early 1990s, it was suggested as a proxy
indicator of 5-year survival, but only for cancer registries
that were unable to compute survival from individual re-
cords for patients with cancer because of a lack of com-
prehensive follow-up.4 The authors even cautioned that
it was not clear whether M/I ratios could provide any
meaningful comparison of survival between cancer
registries.
Unfortunately, the caution expressed by the authors of
the cancer registration manual has been widely ignored.
We argue that, in fact, such comparisons cannot be
safely made.
The evidence we present shows that the 1-M/I ratio is not
a reliable proxy for 5-year net survival, still less for survival at
1 year or 10 years after diagnosis. The difference between
5-year survival and the 1-M/I ratio varies considerably
between cancers, between men and women, between
populations, and for any given cancer, over time. The
completeness of death registration and the accuracy of
selection and coding of the underlying cause of death are
often problematic, especially in low- and middle-income
countries. Above all, cancer incidence and mortality rates
for a given year relate to different cohorts of people.
The M/I ratio is not an estimate of the case-fatality ratio,
which is the proportion of persons diagnosed with a cancer
who die within a speciﬁed period of time, usually within
a few weeks or months. Recently, the 1-M/I ratio has been
formally evaluated as a possible proxy for 5-year relative
survival from publicly available data on incidence, mortality,
and survival for 32 cancers in the Netherlands, the United
States, and the ﬁve Nordic countries.24 This is curious,
because high-quality population-based survival estimates
have been routinely published in all those countries for
many years. The authors commented that the 1-M/I ratio
was a close approximation of 5-year relative survival for
some cancers, but that it was not a valid proxy for all
cancers. They also noted that the degree to which the 1-M/I
ratio deviated from 5-year survival was random. They
nevertheless concluded that “[t]he 1-(M/I) is a good ap-
proximation of the 5-year relative survival for most but not all
tumour sites.”24(p573)
That argument is hard to follow. The inconsistency of the
results, both between cancers and between countries, does
not support the use of the 1-M/I ratio as a valid proxy for
5-year survival for any cancer, whether to examine trends
in survival in a given country or international differences
in survival.
Despite this and the cautions expressed by others,4,25 the
1-M/I ratio has increasingly been used as a proxy for survival
for many cancers, usually without any acknowledgment of
its limitations, even when population-based survival data
are available from the same area. This is most apparent in
the literature on health disparities, where the M/I ratio has
been presented as evidence of cancer survival disparities
by race,26-28 place of birth,29 or sex,26,30 and even as an
indicator of international disparities in cancer screening
and health care.30-34 Other authors have criticized this use.35
One comparison of the 1-M/I ratio with 5-year observed
survival from Lima, Peru, mentioned the absence of studies
“using data from population-based cancer registries in de-
veloping countries to estimate survival,”36(p799) although
several such studies have been published, one of which
included data and participation from Lima.37-40
The M/I ratio has also beenmisused in high-level reviews. A
widely cited report by the Economist Intelligence Unit from
2009 incorrectly referred to the M/I ratio as the “case-
fatality ratio” and the “case-fatality rate,” and then asserted,
also incorrectly, that its complement is the survival [rate].41
Similarly, inDisease Control Priorities: Cancer, published by
the World Bank in 2015, the M/I ratio is incorrectly pre-
sented both as an approximation of the percentage of
people who die of the disease and of the cancer-speciﬁc
mortality rate, for which the unit of measurement is not even
a percentage.42 Most recently, an examination of the
burden of cancer in India within the Global Burden of
Disease Study deployed the M/I ratio to estimate cancer
prevalence as a surrogate for access to cancer care.43
These basic errors in major publications on cancer con-
trol lead to confusion, and to misinterpretation of the epi-
demiologic evidence on cancer survival.
Population-based survival estimates from cancer registry
data summarize the observed duration of survival of indi-
vidual patients with cancer. That is what we want to
know—the probability of survival among a cohort of patients
with cancer who were diagnosed in a given country or region
at a given point in time. These estimates allow us to examine
the decline in survival with time since diagnosis (survival
curves). They enable us to examine variation in survival with
age at diagnosis, between the sexes, by stage at diagnosis,
by socioeconomic status, by race/ethnicity, and between
geographic regions, as well as trends in survival over cal-
endar time, and international differences in survival.
Net survival methods enable us to correct for differences in
background mortality (death from causes other than
cancer) when comparing cancer survival between pop-
ulations or over time.18,44 We can also derive public health
measures, such as statistical cure45-47 or the number of
avoidable premature deaths among patients with cancer48-50
These measures are used to inﬂuence cancer policy and
to evaluate the effectiveness of health systems in cancer
management.51
None of this is possible with the 1-M/I ratio. The 1-M/I ratio
is not an observation of the survival of a cohort of patients
with cancer. It should not be used as an estimate (or
a proxy) of cancer survival.
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